{"id":39089,"date":"2026-06-01T13:32:11","date_gmt":"2026-06-01T11:32:11","guid":{"rendered":"https:\/\/ggba.swiss\/?p=39089"},"modified":"2026-06-01T13:36:35","modified_gmt":"2026-06-01T11:36:35","slug":"mindmaze-secures-chf-8-million-to-expand-its-neurotherapeutics-platform","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/en\/mindmaze-secures-chf-8-million-to-expand-its-neurotherapeutics-platform\/","title":{"rendered":"MindMaze secures CHF 8 million to expand its neurotherapeutics platform"},"content":{"rendered":"\n<p><a href=\"https:\/\/mindmazetherapeutics.com\/\">MindMaze Therapeutics<\/a>, a Geneva-based company specializing in scalable precision neurotherapeutics, entered into a definitive agreement for a CHF 8 million equity financing with <a href=\"https:\/\/neuro.io\/\">Neuro.io Group<\/a>. Through the transaction, Neuro.io will acquire a strategic equity position in the company.<\/p>\n\n\n\n<p>The proceeds will support MindMaze Therapeutics&#8217; commercial priorities, including the expansion of its footprint in the United States and the broader deployment of its neurotherapeutics solutions. The financing is structured in two tranches of treasury share purchases and mandatory convertible loan notes, which are expected to convert into close to 30 million ordinary shares over the following twelve months, strengthening the company&#8217;s balance sheet as it scales operations.<\/p>\n\n\n\n<p>Alongside the financing, the two parties signed a letter of intent to explore a range of strategic opportunities, including a potential business combination. The discussions are expected to focus on pairing MindMaze Therapeutics&#8217; clinically validated neurotherapeutics platform with Neuro.io&#8217;s healthcare-focused AI and computing capabilities to advance AI-enabled interventions targeting neurological disorders.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>MindMaze Therapeutics announced a CHF 8 million strategic equity financing from Neuro.io Group, funding the expansion of its U.S. commercial operations and opening the door to a potential combination of neurotherapeutics and artificial intelligence.<\/p>\n","protected":false},"author":6,"featured_media":39090,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[833],"tags":[893,930,894,890,940],"class_list":["post-39089","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-life-science","tag-artificial-intelligence","tag-digital-health","tag-financing","tag-healthcare","tag-neuroscience"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>MindMaze secures CHF 8 million from Neuro.io Group | GGBa<\/title>\n<meta name=\"description\" content=\"Geneva-based MindMaze Therapeutics announced a CHF 8 million strategic equity financing from Neuro.io Group.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/en\/mindmaze-secures-chf-8-million-to-expand-its-neurotherapeutics-platform\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MindMaze secures CHF 8 million from Neuro.io Group | GGBa\" \/>\n<meta property=\"og:description\" content=\"Geneva-based MindMaze Therapeutics announced a CHF 8 million strategic equity financing from Neuro.io Group.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/en\/mindmaze-secures-chf-8-million-to-expand-its-neurotherapeutics-platform\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-01T11:32:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-01T11:36:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2026\/06\/Mindmaze-GGBa-2026-1180x811-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1180\" \/>\n\t<meta property=\"og:image:height\" content=\"811\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/en\/mindmaze-secures-chf-8-million-to-expand-its-neurotherapeutics-platform\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/en\/mindmaze-secures-chf-8-million-to-expand-its-neurotherapeutics-platform\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"MindMaze secures CHF 8 million to expand its neurotherapeutics platform\",\"datePublished\":\"2026-06-01T11:32:11+00:00\",\"dateModified\":\"2026-06-01T11:36:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/en\/mindmaze-secures-chf-8-million-to-expand-its-neurotherapeutics-platform\/\"},\"wordCount\":169,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/en\/mindmaze-secures-chf-8-million-to-expand-its-neurotherapeutics-platform\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2026\/06\/Mindmaze-GGBa-2026-1180x811-1.png\",\"keywords\":[\"Artificial Intelligence\",\"Digital Health\",\"Financing\",\"Healthcare\",\"Neuroscience\"],\"articleSection\":[\"Life sciences\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/en\/mindmaze-secures-chf-8-million-to-expand-its-neurotherapeutics-platform\/\",\"url\":\"https:\/\/ggba.swiss\/en\/mindmaze-secures-chf-8-million-to-expand-its-neurotherapeutics-platform\/\",\"name\":\"MindMaze secures CHF 8 million from Neuro.io Group | GGBa\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/en\/mindmaze-secures-chf-8-million-to-expand-its-neurotherapeutics-platform\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/en\/mindmaze-secures-chf-8-million-to-expand-its-neurotherapeutics-platform\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2026\/06\/Mindmaze-GGBa-2026-1180x811-1.png\",\"datePublished\":\"2026-06-01T11:32:11+00:00\",\"dateModified\":\"2026-06-01T11:36:35+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"Geneva-based MindMaze Therapeutics announced a CHF 8 million strategic equity financing from Neuro.io Group.\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/en\/mindmaze-secures-chf-8-million-to-expand-its-neurotherapeutics-platform\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/en\/mindmaze-secures-chf-8-million-to-expand-its-neurotherapeutics-platform\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ggba.swiss\/en\/mindmaze-secures-chf-8-million-to-expand-its-neurotherapeutics-platform\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2026\/06\/Mindmaze-GGBa-2026-1180x811-1.png\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2026\/06\/Mindmaze-GGBa-2026-1180x811-1.png\",\"width\":1180,\"height\":811,\"caption\":\"An illustration of neural connectivity, reflecting MindMaze Therapeutics' mission to combine clinically validated neurotherapeutics with AI capabilities to treat neurological disorders.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/en\/mindmaze-secures-chf-8-million-to-expand-its-neurotherapeutics-platform\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MindMaze secures CHF 8 million to expand its neurotherapeutics platform\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/en\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"MindMaze secures CHF 8 million from Neuro.io Group | GGBa","description":"Geneva-based MindMaze Therapeutics announced a CHF 8 million strategic equity financing from Neuro.io Group.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/en\/mindmaze-secures-chf-8-million-to-expand-its-neurotherapeutics-platform\/","og_locale":"en_US","og_type":"article","og_title":"MindMaze secures CHF 8 million from Neuro.io Group | GGBa","og_description":"Geneva-based MindMaze Therapeutics announced a CHF 8 million strategic equity financing from Neuro.io Group.","og_url":"https:\/\/ggba.swiss\/en\/mindmaze-secures-chf-8-million-to-expand-its-neurotherapeutics-platform\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2026-06-01T11:32:11+00:00","article_modified_time":"2026-06-01T11:36:35+00:00","og_image":[{"width":1180,"height":811,"url":"https:\/\/ggba.swiss\/app\/uploads\/2026\/06\/Mindmaze-GGBa-2026-1180x811-1.png","type":"image\/png"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Pierre-Yves Oehrli","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/en\/mindmaze-secures-chf-8-million-to-expand-its-neurotherapeutics-platform\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/en\/mindmaze-secures-chf-8-million-to-expand-its-neurotherapeutics-platform\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"MindMaze secures CHF 8 million to expand its neurotherapeutics platform","datePublished":"2026-06-01T11:32:11+00:00","dateModified":"2026-06-01T11:36:35+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/en\/mindmaze-secures-chf-8-million-to-expand-its-neurotherapeutics-platform\/"},"wordCount":169,"image":{"@id":"https:\/\/ggba.swiss\/en\/mindmaze-secures-chf-8-million-to-expand-its-neurotherapeutics-platform\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2026\/06\/Mindmaze-GGBa-2026-1180x811-1.png","keywords":["Artificial Intelligence","Digital Health","Financing","Healthcare","Neuroscience"],"articleSection":["Life sciences"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/en\/mindmaze-secures-chf-8-million-to-expand-its-neurotherapeutics-platform\/","url":"https:\/\/ggba.swiss\/en\/mindmaze-secures-chf-8-million-to-expand-its-neurotherapeutics-platform\/","name":"MindMaze secures CHF 8 million from Neuro.io Group | GGBa","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/en\/mindmaze-secures-chf-8-million-to-expand-its-neurotherapeutics-platform\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/en\/mindmaze-secures-chf-8-million-to-expand-its-neurotherapeutics-platform\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2026\/06\/Mindmaze-GGBa-2026-1180x811-1.png","datePublished":"2026-06-01T11:32:11+00:00","dateModified":"2026-06-01T11:36:35+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"Geneva-based MindMaze Therapeutics announced a CHF 8 million strategic equity financing from Neuro.io Group.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/en\/mindmaze-secures-chf-8-million-to-expand-its-neurotherapeutics-platform\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/en\/mindmaze-secures-chf-8-million-to-expand-its-neurotherapeutics-platform\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ggba.swiss\/en\/mindmaze-secures-chf-8-million-to-expand-its-neurotherapeutics-platform\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2026\/06\/Mindmaze-GGBa-2026-1180x811-1.png","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2026\/06\/Mindmaze-GGBa-2026-1180x811-1.png","width":1180,"height":811,"caption":"An illustration of neural connectivity, reflecting MindMaze Therapeutics' mission to combine clinically validated neurotherapeutics with AI capabilities to treat neurological disorders."},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/en\/mindmaze-secures-chf-8-million-to-expand-its-neurotherapeutics-platform\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/en\/"},{"@type":"ListItem","position":2,"name":"MindMaze secures CHF 8 million to expand its neurotherapeutics platform"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/en\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/39089","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/comments?post=39089"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/39089\/revisions"}],"predecessor-version":[{"id":39093,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/39089\/revisions\/39093"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/media\/39090"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/media?parent=39089"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/categories?post=39089"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/tags?post=39089"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}